Lust for LIFE: Losartan and type 2 diabetes

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 1, 2003, Pages 45-46

  Brady, Adrian ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

ARBs; Atenolol; Hypertension; Losartan

Indexed keywords

AMLODIPINE; ATENOLOL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; VALSARTAN;

ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STROKE; SUDDEN DEATH; TREATMENT OUTCOME;

EID: 0042388034     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030010601     Document Type: Article

References (10)

1. Dahlof B, Devereux R, Kjeldsen SE et al. Cardiovascular mortality and morbidity in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
2. Lindholm LH, Ibsen H, Dahlöf B et al. Cardiovascular mortality and morbidity in patients with diabetes in the LIFE study. Lancet 2002;359:1004-10.
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
4. Brady AJ, Oliver MA, Pittard JB. Secondary prevention in 24,431 patients with coronary heart disease: survey in primary care. BMJ 2001;322:1463.
5. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. New Engl J Med 1993;329: 1456-62.
6. Bilous RW. Angiotensin II receptor blockade and type 2 diabetic nephropathy. Br J Diabetes Vasc Dis 2002;2:101-05.
7. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
8. Staessen JA, Fagarda R, Thijsa L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.
9. Hansson L, Zanchetti A, Carruthers S et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment study. Lancet 1998; 351:1755-62.
10. Hansson L. The SCOPE trial. Oral Presentation, Hypertension Prague 2002, June 23rd-27th 2002. 19th Scientific Meeting of the International Society of Hypertension joint meeting with 12th European Meeting on Hypertension (European Society of Hypertension).